Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TRICARE keeps retail

Executive Summary

Mail-order will not be mandatory under the Department of Defense's TRICARE program as passed in the Defense Authorization bill (HR 5122), scoring a victory for community pharmacy. The Senate bill contained a provision that would require beneficiaries to use the TRICARE national mail-order program for refills of most long-term maintenance medications, unless waived by the Secretary of Defense based on clinical need, and eliminate cost sharing for most drugs obtained by mail. The House bill would have established lower copays for mail versus retail. While the conference report did not include these provisions, it does state that DOD is expected to "move toward providing a broad range of incentives to increase the use of the TRICARE national mail-order program"...

You may also be interested in...

DOD’s Rx Cost Savings Expected To Double In 2007 As Retail Discounts Bloom

The Department of Defense (DOD) estimates that it will avoid about $900 million in drug costs in fiscal year 2007 through its uniform formulary, more than double the $447 million in savings from fiscal year 2006, according to a recent GAO report on DOD's pharmacy benefits program

Japan Regulators Kept On Track Despite Pandemic

While it was not as affected as some other countries, Japan still had the pandemic to deal with and regulators responded while managing to keep up regular product review work, including several world-first approvals. Coronavirus vaccine roll-outs and the first general annual reimbursement price cut are on the cards for this year. 

QUOTED. 21 January 2021. Larry Biegelsen.

The recently US FDA-cleared Velys robotic-assisted system from DePuy Synthes has distinct features. It also has a small footprint that makes it well-suited for ambulatory surgery centers. See what Larry Biegelsen, an analyst with Wells Fargo, said about it here.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts